These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 38397092)
21. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities. Ligon JA; Ramakrishna S; Ceppi F; Calkoen FGJ; Diorio C; Davis KL; Jacoby E; Gottschalk S; Schultz LM; Capitini CM Transplant Cell Ther; 2024 Feb; 30(2):155-170. PubMed ID: 37863355 [TBL] [Abstract][Full Text] [Related]
22. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. Gu T; Zhu M; Huang H; Hu Y J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535 [TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma. Cai F; Zhang J; Gao H; Shen H Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523 [TBL] [Abstract][Full Text] [Related]
24. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
25. New targets for CAR T therapy in hematologic malignancies. Savani M; Oluwole O; Dholaria B Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226 [TBL] [Abstract][Full Text] [Related]
26. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Huang S; Wang X; Wang Y; Wang Y; Fang C; Wang Y; Chen S; Chen R; Lei T; Zhang Y; Xu X; Li Y Mol Cancer; 2023 May; 22(1):80. PubMed ID: 37149643 [TBL] [Abstract][Full Text] [Related]
27. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling. Bandey IN; Adolacion JRT; Romain G; Paniagua MM; An X; Saeedi A; Liadi I; You Z; Rajanayake RB; Hwu P; Singh H; Cooper LJ; Varadarajan N J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722906 [TBL] [Abstract][Full Text] [Related]
28. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764 [TBL] [Abstract][Full Text] [Related]
29. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Cerrano M; Ruella M; Perales MA; Vitale C; Faraci DG; Giaccone L; Coscia M; Maloy M; Sanchez-Escamilla M; Elsabah H; Fadul A; Maffini E; Pittari G; Bruno B Front Immunol; 2020; 11():888. PubMed ID: 32477359 [TBL] [Abstract][Full Text] [Related]
30. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Yu S; Yi M; Qin S; Wu K Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760 [TBL] [Abstract][Full Text] [Related]
31. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia]. Takahashi Y; Nishio N Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199 [TBL] [Abstract][Full Text] [Related]
32. Applications of single-cell omics for chimeric antigen receptor T cell therapy. Ghaffari S; Saleh M; Akbari B; Ramezani F; Mirzaei HR Immunology; 2024 Mar; 171(3):339-364. PubMed ID: 38009707 [TBL] [Abstract][Full Text] [Related]
33. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320 [TBL] [Abstract][Full Text] [Related]
34. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Zhang P; Zhang Y; Ji N Front Immunol; 2022; 13():927132. PubMed ID: 35874698 [TBL] [Abstract][Full Text] [Related]
35. Better by design: What to expect from novel CAR-engineered cell therapies? Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146 [TBL] [Abstract][Full Text] [Related]
36. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Sun W; Liang AB; Huang H; Huang XJ Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504 [TBL] [Abstract][Full Text] [Related]
37. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176 [TBL] [Abstract][Full Text] [Related]
38. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Guedan S; Alemany R Front Immunol; 2018; 9():2460. PubMed ID: 30405639 [TBL] [Abstract][Full Text] [Related]
39. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914 [TBL] [Abstract][Full Text] [Related]
40. Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019. Bukhari A; Siglin J; Lutfi F; Kansagra AJ; Yared J; Rapoport AP; Dahiya S Crit Rev Oncol Hematol; 2020 Aug; 152():103007. PubMed ID: 32505824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]